vs
Rivian Automotive, Inc.（RIVN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs -63.1%，领先75.8%），Revvity同比增速更快（5.9% vs -25.8%），Revvity自由现金流更多（$161.8M vs $-1.1B），过去两年Revvity的营收复合增速更高（9.0% vs 3.3%）
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RIVN vs RVTY — 直观对比
营收规模更大
RIVN
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出31.7%
-25.8%
净利率更高
RVTY
高出75.8%
-63.1%
自由现金流更多
RVTY
多$1.3B
$-1.1B
两年增速更快
RVTY
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $-811.0M | $98.4M |
| 毛利率 | 9.3% | — |
| 营业利润率 | -64.8% | 14.5% |
| 净利率 | -63.1% | 12.7% |
| 营收同比 | -25.8% | 5.9% |
| 净利润同比 | -9.0% | 3.9% |
| 每股收益（稀释后） | $-0.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RIVNRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.6B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.7B | $729.4M | ||
| Q3 24 | $874.0M | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润RIVNRVTY
| Q4 25 | $-811.0M | $98.4M | ||
| Q3 25 | $-1.2B | $46.7M | ||
| Q2 25 | $-1.1B | $53.9M | ||
| Q1 25 | $-545.0M | $42.2M | ||
| Q4 24 | $-744.0M | $94.6M | ||
| Q3 24 | $-1.1B | $94.4M | ||
| Q2 24 | $-1.5B | $55.4M | ||
| Q1 24 | $-1.4B | $26.0M |
毛利率RIVNRVTY
| Q4 25 | 9.3% | — | ||
| Q3 25 | 1.5% | 53.6% | ||
| Q2 25 | -15.8% | 54.5% | ||
| Q1 25 | 16.6% | 56.5% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | -44.9% | 56.3% | ||
| Q2 24 | -38.9% | 55.7% | ||
| Q1 24 | -43.8% | 54.6% |
营业利润率RIVNRVTY
| Q4 25 | -64.8% | 14.5% | ||
| Q3 25 | -63.1% | 11.7% | ||
| Q2 25 | -85.5% | 12.6% | ||
| Q1 25 | -52.8% | 10.9% | ||
| Q4 24 | -38.1% | 16.3% | ||
| Q3 24 | -133.8% | 14.3% | ||
| Q2 24 | -118.7% | 12.4% | ||
| Q1 24 | -123.3% | 6.8% |
净利率RIVNRVTY
| Q4 25 | -63.1% | 12.7% | ||
| Q3 25 | -75.3% | 6.7% | ||
| Q2 25 | -85.7% | 7.5% | ||
| Q1 25 | -44.0% | 6.4% | ||
| Q4 24 | -42.9% | 13.0% | ||
| Q3 24 | -125.9% | 13.8% | ||
| Q2 24 | -125.8% | 8.0% | ||
| Q1 24 | -120.1% | 4.0% |
每股收益（稀释后）RIVNRVTY
| Q4 25 | $-0.66 | $0.86 | ||
| Q3 25 | $-0.96 | $0.40 | ||
| Q2 25 | $-0.97 | $0.46 | ||
| Q1 25 | $-0.48 | $0.35 | ||
| Q4 24 | $-0.67 | $0.77 | ||
| Q3 24 | $-1.08 | $0.77 | ||
| Q2 24 | $-1.46 | $0.45 | ||
| Q1 24 | $-1.48 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.1B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.6B | $7.3B |
| 总资产 | $14.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RIVNRVTY
| Q4 25 | $6.1B | $919.9M | ||
| Q3 25 | $7.1B | $931.4M | ||
| Q2 25 | $7.5B | $991.8M | ||
| Q1 25 | $7.2B | $1.1B | ||
| Q4 24 | $7.7B | $1.2B | ||
| Q3 24 | $6.7B | $1.2B | ||
| Q2 24 | $7.9B | $2.0B | ||
| Q1 24 | $7.9B | $1.7B |
总债务RIVNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $5.5B | — | ||
| Q1 24 | $4.4B | — |
股东权益RIVNRVTY
| Q4 25 | $4.6B | $7.3B | ||
| Q3 25 | $5.1B | $7.4B | ||
| Q2 25 | $6.1B | $7.6B | ||
| Q1 25 | $6.2B | $7.6B | ||
| Q4 24 | $6.6B | $7.7B | ||
| Q3 24 | $5.9B | $7.9B | ||
| Q2 24 | $6.8B | $7.9B | ||
| Q1 24 | $8.1B | $7.8B |
总资产RIVNRVTY
| Q4 25 | $14.9B | $12.2B | ||
| Q3 25 | $15.2B | $12.1B | ||
| Q2 25 | $15.6B | $12.4B | ||
| Q1 25 | $15.5B | $12.4B | ||
| Q4 24 | $15.4B | $12.4B | ||
| Q3 24 | $14.3B | $12.8B | ||
| Q2 24 | $15.4B | $13.4B | ||
| Q1 24 | $15.7B | $13.4B |
负债/权益比RIVNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.81× | — | ||
| Q1 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-681.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.1B | $161.8M |
| 自由现金流率自由现金流/营收 | -89.0% | 21.0% |
| 资本支出强度资本支出/营收 | 36.0% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-2.5B | $509.4M |
8季度趋势，按日历期对齐
经营现金流RIVNRVTY
| Q4 25 | $-681.0M | $182.0M | ||
| Q3 25 | $26.0M | $138.5M | ||
| Q2 25 | $64.0M | $134.3M | ||
| Q1 25 | $-188.0M | $128.2M | ||
| Q4 24 | $1.2B | $174.2M | ||
| Q3 24 | $-876.0M | $147.9M | ||
| Q2 24 | $-754.0M | $158.6M | ||
| Q1 24 | $-1.3B | $147.6M |
自由现金流RIVNRVTY
| Q4 25 | $-1.1B | $161.8M | ||
| Q3 25 | $-421.0M | $120.0M | ||
| Q2 25 | $-398.0M | $115.5M | ||
| Q1 25 | $-526.0M | $112.2M | ||
| Q4 24 | $856.0M | $149.8M | ||
| Q3 24 | $-1.2B | $125.6M | ||
| Q2 24 | $-1.0B | $136.6M | ||
| Q1 24 | $-1.5B | $129.7M |
自由现金流率RIVNRVTY
| Q4 25 | -89.0% | 21.0% | ||
| Q3 25 | -27.0% | 17.2% | ||
| Q2 25 | -30.5% | 16.0% | ||
| Q1 25 | -42.4% | 16.9% | ||
| Q4 24 | 49.4% | 20.5% | ||
| Q3 24 | -131.9% | 18.4% | ||
| Q2 24 | -89.6% | 19.7% | ||
| Q1 24 | -126.5% | 20.0% |
资本支出强度RIVNRVTY
| Q4 25 | 36.0% | 2.6% | ||
| Q3 25 | 28.7% | 2.6% | ||
| Q2 25 | 35.5% | 2.6% | ||
| Q1 25 | 27.3% | 2.4% | ||
| Q4 24 | 18.9% | 3.4% | ||
| Q3 24 | 31.7% | 3.3% | ||
| Q2 24 | 24.4% | 3.2% | ||
| Q1 24 | 21.1% | 2.7% |
现金转化率RIVNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
